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Identifying and paying for value has become 
a recurrent theme of health care reforms. Its 
corollary, reducing the prevalence of, and 
resources directed to, ineffective or marginally 
effective care, has received far less attention. 
In July 2016, the University of Pennsylvania’s 
Leonard Davis Institute of Health Economics 
(LDI) convened a diverse set of national 
leaders and stakeholders representing industry, 
think-tanks, provider and patient groups, 
and academic experts to tackle how health 
systems, payers, and providers can spur 
the ‘de-adoption’ of medical practices and 
technologies no longer considered valuable. 
While the roundtable of experts unanimously 
supports the need for de-adoption and current 
efforts to curb the use of low-value practices 
or technologies, they identified four specific 
polarities at the heart of the debate about 
how best to build the momentum around de-
adoption, and move it forward. They are:
1)  value (targeting ineffective, even harmful, 
care or expanding efforts to address care 
of limited value)
2)  resource allocation (spending less or 
redirecting spending)
3)  quality improvement (a subset of QI or a 
distinct process)
4)  level of intervention (policy, payment, 
provider, or organization)
In addition to these polarities, several key 
questions emerged that form practical next 
steps for advancing de-adoption activities. With 
an eye toward advancing de-adoption, this brief 
summarizes the polarities and questions that 
suggest priorities for a future research agenda 
and policy-relevant action steps.
The U.S. spends nearly 18% of its GDP ($3.0 
trillion, or $9,523 per person) on health care, 
more than any other country. According 
to the Institute of Medicine, a third of that 
spending could be considered wasteful, in that 
it does not contribute to improving health. 
Nearly one-third of the waste is due to the 
provision of ‘unnecessary services,’ which 
gives us a sense of the scope of the problem, 
but little guidance about which services are 
unnecessary, why they are provided, and 
what to do about it. The expert roundtable 
illuminated the following dimensions that can 
help us develop new better frames for moving 
the debate forward. 
VALUE: TARGETING 
INEFFECTIVE OR MARGINALLY 
EFFECTIVE CARE?
Whether to target ineffective or marginally 
effective care is a key decision in de-adoption 
efforts. The value of a service or product is 
almost always a function of clinical situation 
in which it is used, and capturing that clinical 
nuance can be challenging. However, there is 
a limited set of services in which that clinical 
nuance can be readily and reliably ascertained 
to identify useless, or even harmful, care for 
de-adoption. The advantage of targeting this 
category is the broad support that can be 
leveraged around advocating for de-adoption 
of services that are useless or harmful.  One 
study estimated Medicare spending on 26 
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ISSUES AT THE HEART OF ADVANCING  
THE DE-ADOPTION OF LOW-VALUE CARE 
Proceedings from an expert roundtable  
As background for the roundtable, and to help find a common terminology for 
discussions, LDI reviewed the literature on previous attempts to reduce the use 
of services that do not improve health. While the process by which ineffective 
practices or technologies are abandoned is neither simple nor automatic, even 
the language used to describe it is not clear. And language matters, with different 
terms often reflecting an unstated focus on one intervention mechanism (for 
example, guidelines or payment policy) or one level of decision-making (for 
example, at the bedside or formulary). Disinvestment remains the most commonly 
used term, but may presuppose that the best way to reduce ineffective care is to 
stop paying for it. For the purposes of the roundtable, we chose de-adoption as this 
has been suggested as a term to standardize the literature on low-value clinical care, 
and is more neutral about how we might advance this objective.
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ineffective services that were easily identifiable, 
and readily verifiable, from claims data. The 
study estimated that these services comprise 
between 0.6% and 2.7% of Medicare spending. 
That is a useful baseline about the potential 
savings that can be captured by targeting 
clearly useless services for de-adoption.
Broadening the targets to situations in which 
marginal costs exceeds marginal benefit may 
threaten the support for de-adoption initiatives, 
because it involves both clinical nuance and 
value judgments. On the other hand, targeting 
marginally effective care has a much greater 
potential to bend the health care spending 
curve, because it encompasses a much larger 
set of services and spending. Addressing 
the use of marginally effective care offers 
potentially greater rewards for de-adoption 
efforts, and carries much higher risks. It requires 
value judgments and trade-offs that may be 
politically infeasible, even if it is economically 
efficient. But even a small reduction in such 
care, if it could be ascertained, has greater 
potential to impact health care spending than 
even a large reduction in ineffective care. 
RESOURCE ALLOCATION: 
SPENDING LESS OR 
REDIRECTING SPENDING?
A commonly cited reason for de-adoption 
is to ‘make room’ for medical innovation that 
improves health. Given that innovation is often 
expensive (though perhaps of high-value), de-
adopting services of lesser value would free up 
space in budgets to pay for advances in care.
But does de-adoption actually redirect 
resources in efficient ways, and what is the 
mechanism for doing so? The answer to the 
question is important because it provides the 
motivation for de-adoption, and gives it some 
urgency. In a system of fixed budgets for the 
health care system (for example, the UK’s 
National Health Service), it is easy to argue that 
resources are redirected; it is harder to perceive 
these mechanisms in the pluralistic, multi-payer 
U.S health care system. It is not the case that 
innovation always replaces the technology that 
precedes it. For example, the advent of MRIs 
did not spur de-adoption of CT scans, but 
instead added to spending directed to imaging. 
That additional spending may reduce the 
resources available to other important sectors of 
the economy, but it does not necessarily crowd 
out medical innovation.
In the absence of fixed budgets, one way to 
promote efficient redirection of resources is 
through risk-based payment models, such as 
Accountable Care Organizations (ACOs), 
bundled payments, and shared savings 
programs. In effect, these models create 
incentives for providers to identify and  
discard lower-value services in favor of  
higher-value ones, because providers are  
at risk for the excess spending.  
QUALITY IMPROVEMENT: 
WHERE DOES  
DE-ADOPTION FIT?
How does de-adoption differ from quality 
improvement? A common definition of QI is 
the “…systematic and continuous actions that 
lead to measurable improvement in health 
care services and the health status of targeted 
patient groups.” To the extent that de-adoption 
eliminates harmful care, it clearly overlaps with 
the goals of QI. To the extent that it reduces 
services that are of marginal benefit, it may fall 
outside the scope of QI, especially at a health 
system level, unless that system can redirect 
resources. Hospital global budgeting may bring 
QI and de-adoption into better alignment.
Even when the goals of de-adoption and QI 
overlap, the methods may differ. This is an area 
of fruitful inquiry, given what we know about 
incentivizing behavior change.  A different 
approach may be needed to encourage a 
provider to adopt a practice or process as part 
of QI than to stop delivering a specific practice 
or service. 
AT WHAT LEVEL TO 
INTERVENE: POLICY,  
PAYMENT, PROVIDER,  
OR ORGANIZATION? 
A critical question to answer is the appropriate 
level at which to target de-adoption efforts, 
which may differ depending on the nature of 
the service being de-adopted. For example, 
ADDRESSING THE USE OF 
MARGINALLY EFFECTIVE 
CARE OFFERS POTENTIALLY 
GREATER REWARDS FOR  
DE-ADOPTION EFFORTS, AND 
CARRIES MUCH HIGHER RISKS. 
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the Choosing Wisely campaign targets 
physicians and their patients for conversations 
about care identified as low-value by specialty 
societies. The campaign grounds its efforts 
within a shared decision-making framework 
and targets clinical situations in which services 
are ineffective or harmful.  It remains an open 
question whether the cumulative impact 
of these bedside conversations can have a 
significant impact on the de-adoption of such 
care.
At the payer level, simply not providing 
coverage for low-value services has a direct 
effect on de-adoption. For example, payers can 
remove a service from their coverage criteria. 
However, using payment policy is inherently a 
blunt instrument that may prompt resistance 
from consumers and providers. 
Acting at a health system or institutional level 
may be best for de-adopting some services, 
particularly ones that are hospital-based or 
device-oriented. However, a problem may arise 
at this level if the system has invested many 
of its resources in a technology and needs to 
recoup its investment.
LOOKING AHEAD:  
A RESEARCH AND POLICY 
AGENDA TO INCENTIVIZE THE 
DE-ADOPTION OF LOW-VALUE 
CARE
The roundtable participants identified current 
knowledge gaps and areas of inquiry that they 
considered to be the most promising in terms 
of informing de-adoption initiatives. These six 
areas, with explicit acknowledgement of the 
framing along the dimensions we discussed, 
make up a vibrant research agenda and practical 
next steps for advancing de-adoption activities. 
What is the full potential of 
Choosing Wisely?
Although the provider-led Choosing Wisely 
initiative has an important role to play in 
promoting the de-adoption of low-value care, 
its full potential savings has not been calculated. 
The study mentioned earlier focused on 26 
ineffective services and the potential savings 
for Medicare. But the campaign has more than 
300 recommendations. If all Choosing Wisely 
recommendations were implemented, what are 
the potential savings, and how far would this 
go toward addressing low-value care? What 
institutional, social, and individual changes are 
needed to realize this potential?
Why are practices still in use 
despite evidence of ineffectiveness 
or potential for harm?
Researchers need to build out the set of 
examples that are generally considered harmful 
or ineffective, and yet remain in use, e.g. certain 
cancer screenings. A good starting point 
might be a subset of the services targeted by 
Choosing Wisely, which has had only a marginal 
effect on de-adoption. Taken together, these 
examples provide the raw data to answer 
the questions – Why is this still in practice? 
What are the barriers to de-adoption? What 
interventions might be most effective? 
Conversely, researchers should also build the 
set of examples of practices that have been 
de-adopted, e.g. non-medical labor induction 
prior to 39 weeks. What can be learned about 
incentives and appropriate strategies? When 
there has been a definitive cliff to the de-
adoption of a certain procedure in practice, 
what was the impetus? What is the common 
thread across the examples? What sort of 
change - i.e. payment, guidelines – was effective 
in stopping a practice? 
How do theories of individual 
and institutional behavior change 
apply to de-adoption?
Researchers should look to theories of behavior 
change to understand how to design effective 
interventions, especially considering that de-
adoption entails stopping an existing practice. 
How do behavioral economic principles of 
loss aversion and discounting of long-term 
gains affect providers’ decisions to de-adopt? 
How can framing be used to affect the way 
consumers and providers react to de-adoption 
activities? What is the role of social norms 
and feedback? On an institutional level, can 
diffusion of innovation theory help guide de-
adoption (the final but rarely discussed phase 
of diffusion)? Theories are important, and 
different models of behavior change might be 
appropriate, depending on the specific practice 
and level being targeted.
RESEARCHERS NEED TO 
BUILD OUT THE SET OF 
EXAMPLES THAT ARE 
GENERALLY CONSIDERED 
HARMFUL OR INEFFECTIVE, 
AND YET REMAIN IN USE.
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How can new risk-sharing payment 
models and insurance design 
incentivize de-adoption? 
New risk-sharing payment models provide 
an opportunity to understand and influence 
incentives for the de-adoption of low-value 
care. Researchers should analyze the utilization 
of low-value services in ACOs, as well as 
their non-ACO counterparts. The virtual or 
real infrastructure of an ACO may provide a 
necessary framework for integrating a multi-
level intervention to de-adopt certain services, 
especially if that ACO can redirect its finite 
resources to more effective care.
Risk-sharing relationships and entities are 
also promising vehicles for changing provider 
incentives. As one roundtable participant said: 
“If we can pay farmers not to plant corn, we 
could pay cardiologists to not put in stents.”
Value-based insurance design is gaining 
prominence as a way to align patient cost-
sharing with the effectiveness of treatments. 
Simply put, it encourages patients to use 
services when the clinical benefits exceed the 
cost (by reducing or eliminating cost-sharing) 
and discourages the use of services of marginal 
benefit (by increasing a patient’s out-of-pocket 
costs). This improves upon the strategy of 
simply not paying for a service by letting people 
choose between different plans that have 
different thresholds about low-value care. This 
must be coupled with greater transparency 
about the ‘value’ of different services.
How to determine where and when to 
intervene?
Researchers should develop a de-adoption 
framework that separates out the different levels 
at which to intervene – i.e. policy, organizational, 
payment, provider– and integrates them into a 
cohesive strategy. Depending on the practice, 
it may be that one level is targeted, or that 
multiple levels are targeted, either at the same 
time or sequentially. How might interventions 
interact with each other? Is a ‘Stages of Change’ 
model useful in assessing readiness for change, 
and laying the groundwork at different levels 
over time? This ‘five ways to achieve de-
adoption of low-value care’ would marshal 
existing information but in a new way. 
What does value mean to patients?
A missing, though essential piece in the de-
adoption discussion is a better understanding 
of ‘value’ from a consumer or patient point 
of view. It is key to gaining consensus about 
what to de-adopt, and critical to the success of 
de-adoption initiatives. As the National Health 
Council notes, patient perspectives on value 
can differ significantly from that of physicians 
and payers, often integrating considerations 
beyond clinical outcomes and cost, such as how 
a treatment can help patients achieve personal 
goals. Researchers should build upon existing 
qualitative evidence about patient perspectives 
on value and apply it directly to de-adoption 
activities. It might help explain why services of 
little to no value continue to be offered. This 
evidence could help gain consensus on services 
to target, and engage consumer and patients in 
de-adoption activities.
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